Advances in the Study of Non-Coding RNA in the Signaling Pathway of Pulmonary Fibrosis
DOI: https://doi.org/10.2147/ijgm.s455707
IF: 2.145
2024-04-10
International Journal of General Medicine
Abstract:Dengyun Pan, Xin Di, Bingdi Yan, Xiaomin Su Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, People's Republic of China Correspondence: Bingdi Yan; Xiaomin Su, Department of Respiratory Medicine, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun, 130041, People's Republic of China, Email ; Pulmonary fibrosis is a group of chronic, progressive, and irreversible interstitial lung diseases, which are common to most end-stage lung diseases and are one of the most difficult diseases of the respiratory system. In recent years, due to the frequent occurrence of air pollution and smog, the incidence of pulmonary fibrosis in China has increased year by year, the morbidity and mortality rates of pulmonary fibrosis have gradually increased and the age of the disease tends to be younger. However, the pathogenesis of pulmonary fibrosis is not yet fully understood and is needed to further explore new drug targets. Studies have shown that non-coding RNAs play an important role in regulating the process of pulmonary fibrosis, non-coding RNAs and their specifically expressed can promote or inhibit the process. Here, we review the role of some in the regulation of pulmonary fibrosis signaling pathways and provide new ideas for the clinical diagnosis and treatment of pulmonary fibrosis. Keywords: pulmonary fibrosis, MicroRNA, LncRNA, CircRNA, signaling pathways Pulmonary fibrosis is a terminal change of interstitial lung disease (ILD). It is an abnormal repair process in cases of persistent microdamage to the alveolar epithelium caused by a variety of factors, during which, as the inflammatory response progresses, fibroblasts proliferate and differentiate abnormally, and the extracellular matrix accumulates excessively leading to scar formation in the lung. 1,2 As the disease worsened, altered normal lung tissue structure, reduced compliance, and restricted gas exchange, leading to progressive loss of lung function and eventually respiratory failure and even death. In recent years, the exploration of the pathogenesis and treatment of pulmonary fibrosis at the genomic level has become a major research hotspot, 3 especially in the area of non-coding RNAs (ncRNAs). 4 Non-coding RNAs are RNAs that do not encode proteins. The common feature of these RNAs is that they can be transcribed from the genome, but are not translated into proteins and can perform their respective biological functions at the RNA level. 5 This review focuses on outlining the targets of some miRNAs, lncRNAs, and circRNAs among ncRNAs in the signaling pathway of pulmonary fibrosis, and we look forward to providing a theoretical basis for the clinical management of pulmonary fibrosis. MiRNAs are a class of small ncRNAs about 20–24 nucleotides long encoded by endogenous genes. It is involved in a variety of important physiological and pathological processes in the body, mainly by degrading target mRNAs or inhibiting their translation level through base pairing with the untranslated region at the 3' end of the target mRNA. 6,7 MiRNAs are up- or down-regulated in fibrotic lung tissues. Therefore, they are divided into pro-fibrotic miRNAs and anti-fibrotic miRNAs (Table 1). Hence, targeting these differentially expressed miRNAs could provide a potential therapeutic strategy for pulmonary fibrosis. Table 1 Expression Levels and Targets of miRNAs in Pulmonary Fibrosis Transforming growth factor-β (TGF-β) belongs to the TGF-β superfamily, a group of regulatory cytokines. It plays an essential role in cell growth, differentiation, extracellular matrix synthesis, apoptosis, immunosuppression, and damage repair. Of the three isoforms of TGF-β, TGF-β1 is considered a key factor in the development of pulmonary fibrosis. 8,9 In pulmonary fibrosis, TGF-β1 acts in five ways: 9–14 (1) by promoting extracellular matrix deposition; (2) by promoting the proliferation and aggregation of fibroblasts and their conversion into myofibroblasts; (3) by promoting the epithelial-mesenchymal transition (EMT) process; (4) by regulating immune responses and performing microenvironmental modifications; (5) by acting as a pro-angiogenic factor, to promoting angiogenesis in fibrotic areas; and (6) by inducing multiple cells to secrete senescence-associated secretory phenotypes that drive pulmonary fibrosis through senescence. Smad proteins are a class of intracellular signaling molecules downstream of the TGF-β superfamily, and they play an important role in transmitting TGF-β signals from the extracellular to the nucleus. In the TGF-β/Smad signaling pathway, TGF-β ligands bind to heterodimeric complexes of type II and type I receptors, phosphorylating type II receptors and activating type I receptors. Activated type I receptors phosphorylat -Abstract Truncated-
medicine, general & internal